Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome

The American Academy of Neurology recently held their annual meeting virtually to discuss the latest research in Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). This meeting was held April 17th through 22nd,…

Continue Reading Phase 2 Trial Shows Therapy Reduces Seizures in Dravet Syndrome and Lennox-Gastaut Syndrome
Dravet Syndrome Treatment FINTEPLA (Fenfluramine) Receives Positive CHMP Opinion
esudroff / Pixabay

Dravet Syndrome Treatment FINTEPLA (Fenfluramine) Receives Positive CHMP Opinion

  In mid-October, biopharmaceutical company Zogenix announced that its Dravet syndrome treatment FINTEPLA (fenfluramine) received a positive CHMP opinion. The CHMP is part of the European Medicines Agency (EMA). While…

Continue Reading Dravet Syndrome Treatment FINTEPLA (Fenfluramine) Receives Positive CHMP Opinion
Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial
source: pixabay.com

Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial

According to a story from BioSpace, the biopharmaceutical company Zogenix, Inc., has recently announced the release of results from a phase 3 clinical trial testing the company's drug fenfluramine (marketed…

Continue Reading Recently Approved Treatment for Dravet Syndrome Continues to Show Impacts in Phase 3 Trial
AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome
source: pixabay.com

AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome

As reported in Dravet Syndrome News, in a new study, researchers created an artificial intelligence system which could diagnose epileptic conditions more rapidly and easily than existing systems. Epilepsy is…

Continue Reading AI System Created To Speed Up Epileptic Diagnosis is Tested on Dravet Syndrome
These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
EliasSch / Pixabay

These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies

According to a story from BioSpace, the gene therapy companies Sarepta Therapeutics, Inc. and StrideBio, Inc. have recently announced the completion of a licensing and collaboration agreement that could lead…

Continue Reading These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE
source: pixabay.com

CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE

According to a story from BioPortfolio, the biopharmaceutical company GW Pharmaceuticals plc recently announced that its medicine Epidyolex has earned recommendation from the UK National Institute for Health and Care…

Continue Reading CBD-Based Treatment for Rare Childhood Epilepsies Gets Recommendation from NICE
Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies
geralt / Pixabay

Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

According to a story from sectorpublishingintelligence.co.uk, the drug company Ovid Therapeutics Inc. has recently announced that the early data from its phase 2 clinical trial is mostly encouraging. This clinical…

Continue Reading Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

A Nasal Spray Has Just Become the First New Therapy Approved by the FDA for Cluster Seizures in 20 Years

Cluster Seizures Approximately 1/3 of all epilepsy patients live with uncontrolled seizures. Of these, around 150,000 in the United States alone  experience cluster seizures (otherwise known as acute-repetitive seizures, crescendo…

Continue Reading A Nasal Spray Has Just Become the First New Therapy Approved by the FDA for Cluster Seizures in 20 Years